Last reviewed · How we verify

VERITY — Portfolio Competitive Intelligence Brief

VERITY pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Trelstar triptorelin marketed Gonadotropin Releasing Hormone Receptor Agonist Gonadotropin-releasing hormone receptor Oncology 2000-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Accord Healthcare S.L.U. · 1 shared drug class
  3. Pfizer · 1 shared drug class
  4. Tersera · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for VERITY:

Cite this brief

Drug Landscape (2026). VERITY — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/verity. Accessed 2026-05-15.

Related